Personalis (NASDAQ:PSNL)’s share price traded up 6.9% during trading on Friday . The stock traded as high as $9.52 and last traded at $9.40, 332,230 shares traded hands during trading. A decline of 5% from the average session volume of 348,826 shares. The stock had previously closed at $8.79.
A number of analysts have recently commented on the stock. Bank of America upgraded shares of Personalis from a “neutral” rating to a “buy” rating and set a $22.00 target price on the stock in a report on Thursday, September 26th. Oppenheimer decreased their price target on shares of Personalis from $29.00 to $26.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Finally, Zacks Investment Research cut shares of Personalis from a “buy” rating to a “hold” rating in a research report on Tuesday, November 19th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $23.60.
The company has a 50 day moving average of $10.14.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Board of Trustees of The Leland Stanford Junior University bought a new position in shares of Personalis during the second quarter valued at $38,749,000. Sumitomo Mitsui Trust Holdings Inc. bought a new position in Personalis in the 3rd quarter worth about $11,775,000. Nikko Asset Management Americas Inc. bought a new position in Personalis in the 3rd quarter worth about $11,775,000. JPMorgan Chase & Co. bought a new position in Personalis in the 2nd quarter worth about $17,685,000. Finally, Janus Henderson Group PLC purchased a new stake in Personalis during the 2nd quarter valued at about $13,554,000. 50.46% of the stock is currently owned by hedge funds and other institutional investors.
About Personalis (NASDAQ:PSNL)
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.
Recommended Story: The components of the Stochastic Momentum Index
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.